Having joined Osborne Clarke in 2007, there’s little doubt about Silvia’s specialism – she has devoted her entire career to life sciences and healthcare.

Today, Silvia applies that wealth of knowledge to her role as International Head of the Osborne Clarke Life Sciences and Healthcare team. In doing so, she has worked with a wealth of high-profile clients, both nationally and internationally, including a long-term relationship with one of the world leaders in plasma-based products.

An expert in commercial law, Silvia is often called on for her advisory skills in commercial transactions, as well as regulatory issues around clinical trials and R&D activities, market access, and competition law and anti-corruption compliance. In each instance, her approach is collaborative – in a sector which is evolving rapidly, Silvia works in close co-ordination with every client, keeping pace with change as it happens.

Work

Grifols

Advised on the 60% acquisition of Progenika, a biotechnology firm for €37m.

Grifols

Advised on the acquisition of Talecris for US$4b, creating of one of the world's largest Life Science groups.

Gri-Cel, S.A.

Advised on its acquisition of significant equity stakes in Nanotherapix, VCN Bioscience and Araclon Biotech